U.K. Is First Country to Approve Oxford-AstraZeneca COVID-19 Vaccine
WEDNESDAY, Dec. 30, 2020 -- Britain became the first country to give authorization to the COVID-19 vaccine developed by AstraZeneca and the University of Oxford, The New York Times reported Wednesday.
The British government also decided to start giving as many people as possible a first dose of vaccines, rather than keeping supplies for second shots, expanding the number of people who will be vaccinated.
Some people in clinical trials of the Oxford-AstraZeneca vaccine were given the two doses several months apart. Regulators said that the first dose of the vaccine had 70 percent effectiveness in protecting against COVID-19 in the period between the first dose taking effect and a second shot.
The Oxford-AstraZeneca shot could become the dominant form of inoculation because at $3 to $4 a dose, it is a fraction of the cost of some other vaccines. It can also be shipped and stored in normal refrigerators for six months, rather than in the ultracold freezers needed by vaccines from Pfizer-BioNTech and Moderna.
© 2021 HealthDay. All rights reserved.
Posted: December 2020
Further Support and Information on COVID-19
Read this next
THURSDAY, Jan. 21, 2021 -- Tocilizumab plus standard care is not superior to standard care alone for improving clinical outcomes among patients with severe or critical COVID-19...
THURSDAY, Jan. 21, 2021 -- For adults with COVID-19-related critical illness admitted to the intensive care unit (ICU), mortality has decreased over time, according to a study...
THURSDAY, Jan. 21, 2021 -- A day after his inauguration, President Joe Biden plans to unveil a new, far-reaching pandemic response plan. He will also issue executive orders that...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.